๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Studies with a Chinese investigative site

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the register
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University490 Fudan University472 Second Affiliated Hospital, Zhejiang University, School of Medicine404 Peking Union Medical College Hospital282 Ruijin Hospital281
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to
19052 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma
NCT06383728Lung Cancer, Carcinoma, Squamous Cell
The First Affiliated Hospital of Guangzhou Medical University
Phase 2
51
Guangzhou
2024-04-01
Recruiting
Neural Changes in Stroke Patients During Challenging Walking Tasks.
NCT06764290Stroke
Nanjing Medical University
Observational
60
Nanjing
2024-04-01
Recruiting
UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
NCT06279026Relapsed/Refractory Multiple Myeloma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Not applicable
15
Suzhou
2024-04-01
Not yet open
Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients
NCT06301386Colon Cancer
Fudan University
Phase 2
25
Anyang, Shanghai
2024-04-01
Recruiting
Clinical Study on Dry Needling for Primary Dysmenorrhea and Its Preliminary Correlation With Acupoints
NCT06316583Trigger Point Pain, Myofascial, Acupuncture, Primary Dysmenorrhea
Beijing Hospital
Not applicable
150
Beijing
2024-04-01
Recruiting
The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial
NCT06228794Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
458
Wuhan
2024-04-01
Recruiting
The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma
NCT06316895Papillary Thyroid Cancer
Chinese PLA General Hospital
Observational
3,772
Beijing
2024-04-01
Recruiting
PET Imaging Study of 68Ga-NB381 in Multiple Myeloma
NCT06385652Multiple Myeloma
Peking University First Hospital
Phase EARLY_PHASE1
30
Beijing
2024-04-01
Recruiting
CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention
NCT06283888ACS - Acute Coronary Syndrome, CYP2C19 Polymorphism
Zunyi Medical College
Phase 4
1,200
Zunyi
2024-04-01
Active, closed
Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC
NCT06300424Non Small Cell Lung Cancer, EGFR Gene Mutation
Guangdong Provincial People's Hospital
Phase 2
32
Guangzhou
2024-04-01
Recruiting
Effectiveness and Safety of Sodium Bicarbonate Pleural Lavage in the Treatment of Complex Pleural Effusion
NCT06734481Complicated Pleural Effusion/ Empyema
First Affiliated Hospital of Ningbo University
Not applicable
260
Ningbo
2024-04-01
Recruiting
Effect of Anti-inflammatory Diet in Patients With Inflammatory Bowel Disease
NCT06342011Inflammatory Bowel Diseases
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Not applicable
88
Yiwu
2024-04-01
Recruiting
Application of tDCS Stimulation in Controlling Refractory Status Epilepticus
NCT06344338Refractory Status Epilepticus
Xuanwu Hospital, Beijing
Not applicable
32
Beijing
2024-04-01
Recruiting
Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer๏ผšChase
NCT07555678Anal Squamous Cell Cancer
Fudan University
Phase 2
241
Shanghai
2024-04-01
Recruiting
Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients
NCT06381817Acute T Cell Lymphoblastic Leukemia, Haploidentical Hematopoietic Stem Cell Transplantation, Cord Blood
The First Affiliated Hospital of Soochow University
Phase 3
146
Suzhou
2024-04-01
Recruiting
Effect of Belimumab on Antibody Titers in Primary APS Patients
NCT06747312Antiphospholipid Syndrome (APS)
Ruijin Hospital
Phase 2
20
Shanghai
2024-04-01
Recruiting
Primary Tumor Resection for M1a Stage Lung Cancer
NCT06547710Lung Cancer Metastatic, Surgical Resection
Fudan University
Observational
66
Shanghai
2024-04-01
Recruiting
Fruquintinib Combined With Sintilimab ยฑ Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
NCT06356584Colorectal Cancer, Immunotherapy, Radiotherapy, Targeted Therapy
Shandong Cancer Hospital and Institute
Phase 2
62
Jinan
2024-04-01
Recruiting
Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer
NCT07646145Non-Muscle-Invasive Bladder Cancer (NMIBC)
Shanxi Province Cancer Hospital
Phase 2
30
Taiyuan
2024-04-01
Recruiting
Predicting Ventilator-associated Lower Respiratory Tract Infection Outcomes Using Sequenced-based Early Microbiological Response
NCT06467864Pneumonia, Ventilator-Associated, Respiratory Tract Infections, Prognosis
The First Affiliated Hospital with Nanjing Medical University
Observational
200
Nanjing
2024-04-01
Recruiting
PD-L1 Specific [68Ga]Ga-THP-PDL1-3 Probe for PET Imaging in Solid Tumors
NCT06383598Solid Tumor
Hua Zhu
Not applicable
50
Beijing
2024-04-01
Not yet open
Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy
NCT06332950Extensive-stage Small-cell Lung Cancer
Baohui Han
Phase 1/2
80
Shanghai
2024-04-01
Recruiting
Cardiovascular-Renal Adverse Prognosis Assessment System for Coronary Heart Disease With Chronic Kidney Disease Based on Metabolomics
NCT06383208Chronic Kidney Diseases, Coronary Heart Disease, Lipid Metabolism Disorders
China-Japan Friendship Hospital
Observational
470
Beijing
2024-04-01
Recruiting
A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
NCT06308328Radiation-induced Oropharyngeal Mucositis, Swallowing-induced Breakthrough Pain
Nanfang Hospital, Southern Medical University
Observational
718
Guangzhou, Shaoguan, Shenzhen, Zhuhai, Shanghai, Chengdu
2024-04-01
Recruiting
NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer
NCT06494514Locally Advanced Pancreatic Cancer
Du Juan
Not applicable
40
Nanjing
2024-04-01
Not yet open
Cognitive Impairment Cohort Study of the Elderly Population in YuGarden
NCT06325527Alzheimer Disease, Neurodegenerative Diseases, Cognitive Impairment, Mild Cognitive Impairment
Ruijin Hospital
Observational
1,872
Shanghai
2024-04-01
Recruiting
Washed Microbiota Transplantation for Diabetic Gastroparesis
NCT06340217Diabetic Gastroparesis
The Second Hospital of Nanjing Medical University
Not applicable
46
Nanjing
2024-04-01
Recruiting
The Study of Ginkgo Leaf Dropping Pills and Huperzine A Injection Combined With Median Nerve Electrical Stimulation in the Treatment of Cognitive Impairment After Brain Injury
NCT06704334Cognitive Impairment After Brain Injury
Wanbangde Pharmaceutical Group Co., LTD
Phase 4
50
Ganzhou
2024-04-01
Active, closed
Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy
NCT06305143Diabetic Macular Edema
Shanghai Eye Disease Prevention and Treatment Center
Phase 4
58
Shanghai
2024-04-01
Recruiting
Factors Associated With Posttransplant Cardiac Outcomes
NCT06290154Cardiovascular Diseases, Liver Transplantation
Sun Yat-sen University
Observational
200
Guangzhou
2024-04-01
Recruiting
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial
NCT06256237Limited Stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
30
Shanghai
2024-04-01
Recruiting
Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
NCT06507514B-cell Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University
Phase 1
4
Suzhou
2024-04-01
Recruiting
Early Identification of Malignant Brain Edema in laRge Artery oCclusive Stroke After Endovascular Therapy (EMBRACE Study)
NCT06451887Endovascular Therapy, Brain Edema, Prediction Model, Ischemic Stroke
Zhejiang Provincial People's Hospital
Observational
1,950
Hangzhou
2024-04-01
By invitation
Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC
NCT07359404Advanced Breast Cancer
YING FAN
Phase 2
60
Beijing
2024-04-01
Recruiting
Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer
NCT06525428Microsatellite Stable Metastatic Colorectal Cancer
Fudan University
Phase 2
96
Shanghai
2024-04-01
Recruiting
Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma
NCT06311929HCC
Chen Xiaoping
Phase 4
300
Wuhan
2024-04-01
Recruiting
Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer
NCT06430658Esophagus Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
90
Beijing
2024-04-01
Recruiting
Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma
NCT06749730Unresectable Biliary Tract Carcinoma
Henan Cancer Hospital
Phase 2
63
Zhengzhou
2024-04-01
Not yet open
A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011
NCT06354114Advanced Breast Cancer
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 2
80
Harbin
2024-04
Not yet open
Comparison of Nafamostat and Unfractionated Heparin in RRT for Sepsis Associated AKI
NCT06375616Sepsis
Shen Lei
Phase 4
156
Shanghai
2024-04
Not yet open
A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma
NCT06318884Non-Hodgkin Lymphoma, B-cell
Sinocelltech Ltd.
Phase 1
76
Beijing, Zhengzhou, Tianjin
2024-04
Not yet open
A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma
NCT06368167Follicular Lymphoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
105
Beijing
2024-04
Recruiting
Effect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be-CLEVER)
NCT05976152Stroke, Post-stroke Cognitive Impairment (PSCI)
Fudan University
Phase 3
3,200
Dandong
2024-04
Recruiting
Subarachnoid-Subarachnoid (S-S) Bypass Versus Adhesion Lysis in Spinal Arachnoiditis and Syringomyelia
NCT06375759Syringomyelia
Xuanwu Hospital, Beijing
Not applicable
200
Beijing
2024-04
Recruiting
Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer
NCT06326736Pancreatic Cancer
Jinling Hospital, China
Phase EARLY_PHASE1
12
Nanjing
2024-04
Recruiting
Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma
NCT06553352Follicular Lymphoma, Newly Diagnosed
The First Affiliated Hospital of Xiamen University
Phase 2
39
Xiamen
2024-03-31
Recruiting
Research on Novel Biomarkers for Early Diagnosis of Parkinson's Disease:An Observational, Multicenter, Non-Randomized Controlled Study
NCT06232772Parkinson's Disease
Yousheng Xiao
Observational
600
Nanning
2024-03-31
Recruiting
Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
NCT06988956Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2
95
Nanjing
2024-03-31
Recruiting
A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib
NCT06280105Hepatocellular Carcinoma
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Phase 2
40
Fuzhou
2024-03-31
Recruiting
The Clinical Significance of CT-based Biomarkers in the Classification and Prognosis of Bronchiectasis
NCT06346938Bronchiectasis
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
300
Wuhan
2024-03-30
Recruiting
Goal-directed Enteral Nutritional Perioperative Management
NCT06510543Esophagus Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
400
Beijing, Chongqing, Fuzhou, Anyang, Zhengzhou, Huai'an, Nanjing, Jinan
2024-03-30
Recruiting
Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection
NCT06461351B-cell Tumors
Juventas Cell Therapy Ltd.
Observational
1,000
Tianjin
2024-03-30
By invitation
Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
NCT06690216Glioblastoma (GBM), Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer
Man Hu
Phase 1/2
100
Jinan
2024-03-30
Active, closed
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
NCT06254950Ulcerative Colitis
Takeda
Phase 2
213
Chongqing, Guangzhou, Changsha, Changzhou, Shenyang, Shanghai, Chengdu, Hangzhou
2024-03-29
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
Alexion Pharmaceuticals, Inc.
Phase 3
579
Baotou, Beijing, Changsha, Changzhou, Chengdu, Chongqing, Guangzhou, Hangzhou
2024-03-29
Recruiting
Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy
NCT06385990Triple Negative Breast Neoplasms
Hunan Cancer Hospital
Phase 2
53
Changsha
2024-03-29
Recruiting
Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy
NCT05514015Primary Membranous Nephropathy
First Affiliated Hospital, Sun Yat-Sen University
Phase 4
78
Guangzhou
2024-03-29
Recruiting
Comparison of Transcatheter Edge-to-edge Repair Using Echo Only with Echo Combined with X Ray for Mitral Regurgitation (ECHO-CLIP)
NCT06684171Mitral Regurgitation
Pan Xiangbin
Not applicable
200
Shenzhen
2024-03-29
Not yet open
To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma
NCT06298266Relapsed or Refractory Multiple Myeloma
Guangdong Second Provincial General Hospital
Phase EARLY_PHASE1
15
Guangzhou
2024-03-29
Recruiting
A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children
NCT06305663Myopia
Bausch & Lomb Incorporated
Not applicable
418
Beijing, Dongcheng, Xiamen, Haikou, Wuhan, Shanghai, Taiyuan, Shenzhen
2024-03-29
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873Chronic Kidney Disease and Hypertension
AstraZeneca
Phase 3
2,554
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dongguan
2024-03-29
Active, closed
Study of JK07 in Patients With Chronic Heart Failure
NCT06369298Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Salubris Biotherapeutics Inc
Phase 2
282
Changsha, Nanjing, Jining, Chengdu, Beijing, Chongqing
2024-03-28
Active, closed
Septal Ablation for Obstructive HCM
NCT06277960Hypertrophic Obstructive Cardiomyopathy (HOCM)
SuZhou Sinus Medical Technologies Co.,Ltd
Not applicable
20
Hangzhou
2024-03-28
Active, closed
A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
NCT06984588Non Small Cell Lung Cancer
TJ Biopharma Co., Ltd.
Phase 2/3
450
Anyang, Beijing, Bengbu, Binzhou, Changsha, Chongqing, Dongguan, Foshan
2024-03-28
Recruiting
Adjuvant Hypofractionated Radiotherapy for Prostate Cancer
NCT06335693Prostate Cancer
Changhai Hospital
Not applicable
9
Shanghai
2024-03-28
Recruiting
CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer
NCT06281405Locally Advanced Rectal Cancer, Neoadjuvant Therapy
Fudan University
Phase 2
192
Shanghai
2024-03-28
Recruiting
The Correlation of Intracranial Artery Calcification and Outcomes of Mechanical Thrombectomy
NCT06418698Stroke, Acute, Ischemic Stroke, Vascular Diseases, Central Nervous System Diseases
Zhujiang Hospital
Observational
434
Guangzhou
2024-03-28
By invitation
Videodensitometric Angiographic Assessment of AR in the Cath-lab for Intraprocedural Guidance of TAVI in CHINA
NCT06891079Aortic Stenosis
Xijing Hospital
Not applicable
320
Shanghai, Xi'an
2024-03-28
Recruiting
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
NCT06300177Non Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
522
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Zhanjiang
2024-03-28
Recruiting
Phase III Clinical Study of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease
NCT06879782Dry Eye Disease (DED)
Lunan Better Pharmaceutical Co., LTD.
Phase 3
820
Beijing
2024-03-28
Recruiting
Early Lumbar Drainage Plus Intrathecal Urokinase in Severe Aneurysmal Subarachnoid Hemorrhage (LD-ITUK)
NCT06284642Aneurysmal Subarachnoid Hemorrhage
Second Affiliated Hospital of Nanchang University
Phase 4
424
Hefei, Heihe, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2024-03-28
Recruiting
A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors
NCT06307925Advanced Solid Tumor
HC Biopharma Inc.
Phase 1
122
Guangzhou
2024-03-27
Recruiting
Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain
NCT07008703Cancer Pain
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 1/2
132
Zhengzhou
2024-03-27
Recruiting
A Study of CS23546 in Subjects With Advanced Tumors
NCT06245122Advanced Tumors
Chipscreen Biosciences, Ltd.
Phase 1
156
Guangzhou
2024-03-27
Recruiting
A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors
NCT05983523Advanced Solid Tumor, Metastatic Solid Tumor
PharmaEngine
Phase 1
54
2024-03-27
Recruiting
68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.
NCT06613269Clear Cell Renal Cell Carcinoma
Peking Union Medical College Hospital
Phase 2
40
Beijing
2024-03-27
Recruiting
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
NCT06464991Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd.
Phase 3
240
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang
2024-03-27
Active, closed
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06290934Ulcerative Colitis
Gilead Sciences
Phase 2
228
2024-03-27
Active, closed
A Study of Efficacy and Safety of TLL-018 in CSU Participants
NCT06396026Chronic Spontaneous Urticaria
Hangzhou Highlightll Pharmaceutical Co., Ltd
Phase 3
440
Nanjing
2024-03-27
Recruiting
Human Interferon ฮฑ1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections
NCT06363370Respiratory Syncytial Virus Infections
Kexing Biopharm Co., Ltd.
Phase 3
322
Beijing
2024-03-27
Recruiting
Physiological Study of High PEEP in Noninvasive Ventilation
NCT07503509Respiratory Failure With Hypoxia
Chongqing Medical University
Not applicable
50
Chongqing
2024-03-26
Not yet open
A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors
NCT06300216Neuroendocrine Tumors
Qilu Hospital of Shandong University
Observational
500
Jinan
2024-03-26
Active, closed
An Observational Cohort Study to Explore the Clinical Outcome of Congenital Strabismmus Based on Etiology and Timing of Surgery
NCT06614335Congenital Esotropia
Qiyu Bo
Observational
300
Shanghai
2024-03-26
Recruiting
Evaluation of the Water Vapor Thermal Therapy System for the Treatment of Benign Prostatic Hyperplasia
NCT06725212Benign Prostatic Hyperplasia
Medtecx Co Ltd.
Not applicable
126
Hefei, Beijing, Wuhan, Nanjing, Nanchang, Xi'an, Shanghai, Tianjin
2024-03-26
Recruiting
Study of IBR733 Cell Injection in Acute Myeloid Leukemia
NCT06234904Acute Myeloid Leukemia
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 1
18
Suzhou
2024-03-26
Recruiting
Development and Validation of an Anxiety Disorder Prediction Model for Premature Ejaculation Patients
NCT06677814Premature Ejaculation, Anxiety
Xijing Hospital
Observational
700
Xi'an
2024-03-25
Active, closed
Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody
NCT06432296Malignant Ascites
Wuhan YZY Biopharma Co., Ltd.
Phase 3
312
Beijing, Harbin
2024-03-25
Recruiting
Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma
NCT06323369Head and Neck Squamous Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
154
Guangzhou
2024-03-25
Recruiting
Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma.
NCT06533267Nasopharyngeal Carcinoma, Intensity Modulated Radiotherapy, Surgery
Sun Yat-sen University
Not applicable
442
Zhuhai
2024-03-25
Recruiting
Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
NCT06484829Relapsed or Refractory Multiple Myeloma (RRMM)
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 1/2
144
Chengdu
2024-03-25
Recruiting
CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial)
NCT06242418Colon Cancer
West China Hospital
Phase 2
60
Guiyang, Chengde, Chengdu, Kunming
2024-03-25
Recruiting
Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer.
NCT06642857Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma
Xiangdong Cheng
Observational
150
Hangzhou
2024-03-25
Recruiting
Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma
NCT06340204Ewing Sarcoma
Peking University People's Hospital
Phase 1
44
Jina, Beijin, Beijing
2024-03-25
Active, closed
A Study of IL4Rฮฑ Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).
NCT06315426Allergic Rhinitis
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 2
240
Langfang, Xingtai, Zhengzhou, Jingzhou, Wuhan, Jinan, Liaocheng, Changzhi
2024-03-24
Recruiting
Improving Patient-reported Outcomes After Lung Cancer Surgery With Mobile Internet Platform
NCT06483295Lung Cancer
Shanghai Chest Hospital
Not applicable
216
Shanghai
2024-03-24
Active, closed
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
NCT06257875Ulcerative Colitis
AbbVie
Phase 2
156
2024-03-23
Recruiting
Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis
NCT04968509Aortic Stenosis
Beijing Anzhen Hospital
Phase 3
160
Beijing
2024-03-22
Recruiting
A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer
NCT06292689Vulvar and Vaginal Cancer
Zhejiang Cancer Hospital
Phase 2
40
Hangzhou
2024-03-22
Recruiting
A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)
NCT06222671Axial Spondyloarthritis
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2
180
Beijing, Chongqing, Zhengzhou, Nanjing, Shenzhen
2024-03-22
Active, closed
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
NCT06380660Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer
Acerand Therapeutics (Shanghai) Limited
Phase 1/2
298
Chongqing, Fuzhou, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha, Jinan
2024-03-22
Rows per page Showing 13201–13300 of 19052
Previous 131 132 133 134 135 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china?page=133

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
→

Browse trials by condition

Breast Cancer (416) Advanced Solid Tumors (183) Gastric Cancer (183) Colorectal Cancer (179) Hepatocellular Carcinoma (161) Advanced Solid Tumor (159) Solid Tumor (145) Non-Small Cell Lung Cancer (144) Acute Ischemic Stroke (138) Lung Cancer (134) Pancreatic Cancer (132) Non-small Cell Lung Cancer (131) Multiple Myeloma (126) Coronary Artery Disease (111) Prostate Cancer (111)
→

Browse trials by site location

Beijing (5484) Shanghai (3827) Guangzhou (3318) Hangzhou (1812) Wuhan (1343) Chengdu (1291) Nanjing (1193) Changsha (1154) Chongqing (1056) Fuzhou (1018) Tianjin (940) Zhengzhou (921) Hefei (875) Jinan (785) Changchun (641)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.